Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ceribell, Inc.CBLL · Entity 4994 | Director | July 28, 2026 | July 30, 2026 |
| HOLOGIC INCHOLX · Entity 12463 | Div President & GM, Diagnostic | December 01, 2018 | December 04, 2018 |
| Inogen IncINGN · Entity 2083 | Director | June 05, 2024 | June 07, 2024 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director · President and CEO | May 13, 2022 | May 16, 2022 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ceribell, Inc.
Report date July 28, 2026 · Filed July 30, 2026
This filing explicitly reported no securities owned.
HOLOGIC INC
Report date December 01, 2018 · Filed December 04, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,753 |
Reported balance
After 2018-12-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-12-01 · Tax withholding · Disposed 1,011 · Balance 55,753 F1: Includes 34,527 restricted stock units/performance share units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 34,527 restricted stock units/performance share units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.
Inogen Inc
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,677 |
Reported balance
After 2024-06-05 transaction · row 1
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 21,871 · Balance 40,677 F1: The reported shares wee acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares wee acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting schedule.
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-05-13 · Other · Disposed 39,700 · Balance 312,048 F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 2 · 2022-05-13 · Other · Disposed 104,456 · Balance 207,592 F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Row 3 · 2022-05-13 · Other · Disposed 207,592 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2030-02-03 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-13 · Other · Disposed 78,700 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.07 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-13 · Other · Disposed 118,461 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.44 · Expires 2029-07-21 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-13 · Other · Disposed 97,960 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.44 · Expires 2029-07-21 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-13 · Other · Disposed 427,147 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchaser Issuer Common Stock that is subject to performance-based vesting conditions that was outstanding and unexercised and became vested immediately prior to or upon the Effective Time (each, a 'Vested Performance Based Option') was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Performance Based Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Vested Performance Based Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F2: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].
F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchaser Issuer Common Stock that is subject to performance-based vesting conditions that was outstanding and unexercised and became vested immediately prior to or upon the Effective Time (each, a 'Vested Performance Based Option') was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Performance Based Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Vested Performance Based Option, subject to any required withholding of taxes.
SI-BONE, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,947 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,957 · Balance 37,947 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 20,115 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.
F2: Includes 20,115 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orthofix Medical Inc.
Report date December 31, 2022 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,055 |
Reported balance
After 2022-10-31 transaction · row 1
1 source rowRow 1 · 2022-10-31 · Grant · Acquired 512 · Balance 7,055 F1: Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022. F2: Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022.
F2: Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2016 Filed Dec 6, 2016 00:42 UTC | HOLOGIC INC HOLX · Entity 12463 | GrantCommon Stock | 8,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-069203 · form4.xml · nonDerivative · entry 2 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,059 F3 · shares: Represents RSUs which vest in equal installments on each of the first three anniversaries of the grant date and are settled in shares of common stock. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. F4 · balance_after: Includes 7,841 shares subject to deferral pursuant to the Issuer's Deferred Equity Plan. Read SEC document |
| November 05, 2016 Filed Dec 6, 2016 00:42 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 2,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-069203 · form4.xml · derivative · entry 3 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,171 Underlying: Common Stock · 2,085 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis upon vesting. F1 · timeliness: Represents vested RSUs that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: Represents RSUs which vest in equal installments on each of the first three anniversaries of the grant date and are settled in shares of common stock. F3 · derivative.expiration_date: Represents RSUs which vest in equal installments on each of the first three anniversaries of the grant date and are settled in shares of common stock. Read SEC document |
| November 05, 2016 Filed Dec 6, 2016 00:42 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 2,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-069203 · form4.xml · nonDerivative · entry 1 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · timeliness: Represents vested RSUs that are subject to deferral pursuant to the Issuer's Deferred Equity Plan and are voluntarily being reported on Table 1. F2 · price: RSUs convert into common stock on a one-for-one basis upon vesting. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:10 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionRestricted Stock Unit Award (Right To Receive) · Derivative | 4,063 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001127602-16-063993 · form4.xml · derivative · entry 3 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,127 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (RSUs) convert into common stock on a one-for-one basis upon vesting. F3 · derivative.exercise_date: This RSU award vests in four equal installments beginning on first anniversary of the grant date. F3 · derivative.expiration_date: This RSU award vests in four equal installments beginning on first anniversary of the grant date. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:10 UTC | HOLOGIC INC HOLX · Entity 12463 | Tax withholdingCommon Stock | 1,564 | $38.80 | $60,683.20 |
DisclosureSEC source: 0001127602-16-063993 · form4.xml · nonDerivative · entry 2 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,340 F2 · balance_after: Includes 805 shares acquired pursuant to the Issuer's employee stock purchase plan since the date of the Reporting Person's most recently filed Form 4. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 20:10 UTC | HOLOGIC INC HOLX · Entity 12463 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-16-063993 · form4.xml · nonDerivative · entry 1 West Thomas A. · CIK 0001620705 · Div President & GM, Diagnostic 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units (RSUs) convert into common stock on a one-for-one basis upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.